Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Aclarion, Inc. - Common Stock (NQ: ACON )

0.1789 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aclarion, Inc. - Common Stock

< Previous 1 2 Next >
Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st
Via ACCESSWIRE
Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Aclarion Provides Corporate Update on Nociscan AI Technology Milestones
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Aclarion, Inc.’s (NASDAQ: ACON) Emerging Role in the Back Pain Management Sector
Via AB Newswire
Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial
Initial LIFEHAB Enrolled Patients Receive Nociscan Exams to Help Evaluate How Biomarkers in the Discs of the Lumbar Spine Correspond With Treatment Response 
Via NewMediaWire
Aclarion Launches Surgeon Partnership to Apply Nociscan's AI Technology to Personal Injury and Workers Compensation Market
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan's AI Generated Biomarker Data Changes Surgical Treatment Plans
Via NewMediaWire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Aclarion to Present at August 20th Virtual Investor Summit Microcap Event
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Aclarion Announces First Commercial Agreement in Michigan
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Aclarion Hits Another Key Milestone by Adding Vitality - Third Major Payer to Cover Nociscan in Greater UK
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Aclarion Receives Notice of Allowance for US Patent to Support Further Optimization of Accuracy and Reliability in the Nociscan Solution
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property
Aclarion Receives Notice of Allowance for US Patent to Support Further Optimization of Accuracy and Reliability in the Nociscan Solution
Notice of Allowance is for the 23rd US Patent to be Awarded to Aclarion 
Via TheNewswire.com
Topics Intellectual Property
Exposures Intellectual Property
Aclarion Announces Updated Product Release That Enhances User-Experience, Scalability, and Security for Nociscan Solution
Nociscan is the first augmented intelligence platform to measure pain biomarkers in the lumbar spine. 
Via TheNewswire.com
Topics Artificial Intelligence
Exposures Artificial Intelligence
Aclarion Announces Updated Product Release That Enhances User-Experience, Scalability, and Security for Nociscan Solution
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Aclarion's Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Aclarion to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Aclarion to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 &amp; 1x1 Meetings on Thursday, May 2, 2024
BROOMFIELD, CO - (NewMediaWire) - April 23, 2024 - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary... 
Via TheNewswire.com
Aclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar Discs
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Aclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar Discs
Confirms predictive value of Nociscan for identifying painful discs. 
Via TheNewswire.com
Aclarion Announces Closing of $3.0 Million Public Offering
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Aclarion Announces Closing of $3.0 Million Public Offering
BROOMFIELD, CO - (NewMediaWire) - February 27, 2024 - Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary... 
Via TheNewswire.com
Aclarion Announces Pricing of $3.0 Million Public Offering
BROOMFIELD, CO - (NewMediaWire) - February 26, 2024 - Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary... 
Via NewMediaWire
Aclarion Announces Pricing of $3.0 Million Public Offering
BROOMFIELD, CO - (NewMediaWire) - February 26, 2024 - Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary... 
Via TheNewswire.com
Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership
Company is initiating its pivotal multicenter, prospective, randomized CLARITY trial to build on clinical evidence demonstrating superior surgical outcomes when Nociscan is utilized in surgical... 
Via NewMediaWire
Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership
Company is initiating its pivotal multicenter, prospective, randomized CLARITY trial to build on clinical evidence demonstrating superior surgical outcomes when Nociscan is utilized in surgical... 
Via TheNewswire.com
Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.